We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Immunosignaturing Platform Provides Pre-Symptom Diagnostics

By LabMedica International staff writers
Posted on 21 Feb 2017
Researchers have developed an immunosignature profiling technology aimed to provide people with a means of monitoring their health status and a means for early detection of disease by rapidly testing for many diseases at once from a single drop of blood. More...
In addition, the versatile technology could be used to secure a nation’s blood supply or give early warning of a disease epidemic.

An international group of scientists, inventors, and entrepreneurs are bringing this invention to fruition and “will give people a deeper understanding of the medical, behavioral, and environmental factors that can accelerate disease or optimize health,” according to a recent announcement by Prof. Jun Wang, iCarbonX founder and creator of the Digital Life Alliance, based in Shenzhen, China.

ImmunoSignature, the diagnostic platform developed by a team led by Prof. Stephen Albert Johnston and Prof. Neal Woodbury of Arizona State University (ASU) Biodesign Institute, was a critical final piece needed to complete iCarbonX's potentially revolutionary approach to healthcare. With a single drop of blood, the platform can detect diseases that involve an immune response (e.g. autoimmune, cancer, infectious disease, metabolic, and neurologic diseases). The team has already successfully demonstrated the potential of immunosignaturing for diagnosing over 50 diseases, including diabetes, cancer, and Alzheimer’s.

“My goal has always been to detect illness before it begins,” said Prof. Johnston, adding that he predicts that the technology to track and report disease biomarkers directly to patients could be available within 5 years. Backed by a USD 400 million investment, the Digital Life Alliance aims at producing a personalized health guide, and will, according to Prof. Wang, “merge genetic, biological, and patient-generated data with sequencing and AI (artificial intelligence) technology to instantly detect meaningful signals about health, disease and aging, and deliver a personalized guide for living a healthy life.”

“Scientists with expertise, imagination, and boundless aspiration are who we recruit to Arizona, ASU, and Biodesign,” said ASU President Michael Crow, “Today we are being recognized as a powerhouse in the world of innovation and for generating use-inspired solutions. iCarbonX’s significant investment in technologies conceived at ASU is a real demonstration of what can happen when public and private enterprises bring their best minds together.” Launched in 2004, ASU’s Biodesign Institute represents the state’s largest single investment in research infrastructure in the history of Arizona.

Digital Life Alliance includes HealthTell as one of 7 core companies. According to Prof. Johnston, HealthTell’s high-density peptide array platform is the first real-time assessment that will be simple, inexpensive, and comprehensive. The HealthTell technology, particularly when combined with data from the other Digital Life Alliance partners, has the potential to enable health monitoring on a regular basis using single-drop blood samples.

Catching diseases early save lives, helps eradicate challenges faced by those who suffer from illness, and results in cost savings. Some of the leading causes of disease – both infectious and chronic – give rise to immune responses fairly early. Immunosignatures of antibody patterns that indicate early-response would provide snapshots for monitoring a person’s health as well as a more detailed picture of health status.

“The idea is to change medicine from post-symptomatic to pre-symptomatic. To do that, you have to monitor healthy people and figure out early what’s happening to them,” said Prof. Johnston, With our rapidly aging population and collaborative spirit, he envisions Arizona as a possible “R&D proving ground” to help get ahead of disease and its costs. We “will continue to push the envelope on what health and disease information we can glean from immunosignatures,” he said.

“We can only reach this audacious goal if we successfully integrate traditionally separate fields of expertise into one collaborative ecosystem,” said Prof. Wang. As former CEO of the Beijing Genomics Institute, he has built the world’s largest DNA sequencing hub, which aims to make genomic information a routine part of medical checkups. His iCarbonX ecosystem includes HealthTell, SomaLogic, PatientsLikeMe, AOBiome, GALT, Imagu, and Robustnique.


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
PlGF Test
Quidel Triage PlGF Test
New
PSA Assay
CanAg PSA EIA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.